Alerta

METHODS OF TREATING LUNG CANCER AND OTHER CANCERS BY RECOMBINANT SARS-COV-2 SPIKE S1

Resumen de: US20260139008A1

Described herein is a novel method of treating cancer in a patient in need thereof, comprising administering a therapeutically effective amount of SARS-CoV-2 Spike 51 polypeptide.

Colorimetric and Multiplexed Isothermal RNA- and Antibody-Based Assay for SARS-CoV-2 and Other Viral Diagnostics and Cell Analysis

Resumen de: US20260139332A1

0000 Methods, devices, and kits for performing rapid, highly sensitive, high throughput, accurate, and flexible detection and quantification of antigens based on highly optimized rolling circle amplification are provided. The methods, devices, and kits can be used to detect and track an emergent virus or other pathogen, including SARS-COV-2, to test and diagnose individual patients with respect to a specific pathogen or disease, including COVID-19, and to detect and analyze cellular nucleic acids. The methods and devices also can be used to detect fragments and variants of DNA or RNA, including those present in cancer cells. The methods, devices, and kits are suitable for use in both high throughput screening carried out in centralized testing laboratories and in point-of-care testing devices used in the field, at home, in the workplace, or at public facilities for rapid detection and diagnosis.

PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS

Resumen de: US20260139860A1

In alternative embodiments, provided are products of manufacture, including automobiles and buildings, and multiplexed systems such as ventilation systems, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, coronavirus (such as a SARS, MERS or COVID-19 infection), or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales.

VARIANT STRAIN-BASED CORONAVIRUS VACCINES

Resumen de: US20260137772A1

The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-COV-2, as well as methods of using the vaccines.

AIR FILTER WITH PATHOGEN MONITORING AND INACTIVATION

Resumen de: US20260137077A1

An improved technology for inactivation of viruses, for example the SARS-COV-2 virus that is causing the Covid-19 pandemic, is described. The technology can include a device that includes a substrate coated in a polymer that is infused with a pathogen inactivating material. In various embodiments, at a given time, a portion of the pathogen inactivating material is exposed to the environment, and the device is configured to periodically or intermittently expose additional pathogen inactivating material to the environment. For example, the polymer can be ablative or sacrificial.

HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF

Resumen de: US20260139035A1

It is an object of the present invention to provide an antibody against coronavirus (SARS-CoV-2) variants. It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. The present invention provides an antibody or antigen-binding fragment thereof that binds to the spike protein of the coronavirus and has the ability to neutralize coronaviruses, including the Omicron variant, and a pharmaceutical composition for the prevention or treatment of coronavirus infection, which contains the antibody or an antigen-binding fragment thereof.

SYSTEM FOR CARGO TRANSPORT

Resumen de: US20260138838A1

A system for cargo transport in the field of intermodal logistics aims to solve supply chain-related disruptions experienced during the Covid-19 pandemic. Cargo frame cargo ships (24), cargo frame barges (26), cargo frame docks (20), 3-axis structures, and 3-axis hoists (10) utilize a cargo frame to bundle series 1 freight containers, vehicles, dry-bulk, wet-bulk, and other general cargoes in a stackable, modular manner. Purpose-built 3-axis structures increase the footprint of ports where cargo frames are stacked, stored, and retrieved. Semi-truck queueing towers (22), and freight car transshipment yards (34) allow for timely coordination of cargo transfer at a multi-level port (48), increasing the throughput of intermodal cargoes.

Aptamers specifically binding to human coronavirus and use thereof

Resumen de: KR20260072673A

본 발명은 인간 코로나바이러스에 특이적으로 결합하는 압타머와 이의 용도에 관한 것으로, 본 발명에서 발굴한 코로나바이러스에 특이적으로 결합하는 신규한 압타머들은 종래의 항체에 비해 온도 및 pH에 안정적이며, 투여가 용이하고, 변형이 용이한 장점이 있으며, 피코몰(pM) 수준의 높은 결합 친화도로 SARS-CoV-2 spike 단백질의 subunit 2에 고특이적으로 결합하고, 코로나바이러스와 숙주 세포 사이의 막 융합을 억제함으로써 바이러스의 숙주 세포로의 유입을 억제하는 효가가 있으므로, 코로나바이러스의 검출, 감염 진단, 감염증의 예방 및 치료 용도로 활용할 수 있다.

THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION

Resumen de: US20260139062A1

The present invention provides a pharmaceutical composition for use in therapy or prevention of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19), the composition containing an IL-10 inhibitor.

PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2

Resumen de: US20260137677A1

0000 Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; Mcomprises a SARS-CoV-<2 >main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and Ucomprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.

EVOLUTION OF FLUOROGENIC SENSORS

Nº publicación: US20260139001A1 21/05/2026

Solicitante:

PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
MASSACHUSETTS INST OF TECHNOLOGY [US]
President and Fellows of Harvard College
Massachusetts Institute of Technology

Resumen de: US20260139001A1

Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (e.g., Omicron variants).